Saturday, May 02, 2026
In Detail Full day, Saturday, May 02, 2026, Timezone: America/Chicago
6 Things to Know About Medtronic’s Cyberattack
Katie Adams / medcitynews - Medtronic suffered a cyberattack on its corporate IT systems. The incident highlights growing cybersecurity risks in the medtech sector, with cybergangs increasingly using phishing and other human-engineering tactics to gain access to data.The post 6 Thin…
AI Summary: Medtronic reported an IT systems breach following a cyberattack, prompting an internal probe and operational mitigation efforts. The company is assessing clinical and supply impacts, notifying stakeholders, and coordinating with cybersecurity authorities — a reminder that even medtech giants are not immune to the digital snarls that can ripple through patient care and profits.
Vivek Subbiah: F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer
oncodaily - Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Wow! It’s Big news on Friday. F.D.A. Grants Early Access to Promising Drug for […]
AI Summary: The FDA has authorized early access to a promising experimental therapy for pancreatic cancer, opening an expanded‑access pathway so eligible patients can receive the drug before full approval. Regulators based the decision on encouraging early clinical signals of activity and manageable safety data, aiming to offer options for a disease with few effective treatments—because pancreatic cancer isn’t known for its patience.
- Daraxonrasib expanded access: FDA opens early pathway (6)
- Research advances: diagnostics and targeted therapies for pancreatic cancer (5)
- All Other Stories
Daraxonrasib expanded access: FDA opens early pathway
Research advances: diagnostics and targeted therapies for pancreatic cancer
All Other Stories
Runners have finally completed a sub 2-hour marathon, but another running world record was recently smashed — this time by a humanoid robot. Here's how.
livescience - The D1 humanoid robot, built by a smartphone manufacturer, has beaten the human-held world record by around seven minutes.
AI Summary: Two elite athletes have crossed a long-standing human performance line by completing a marathon in under two hours, a landmark moment for endurance sport. The achievement rewrites expectations, prompts fresh debate about pacing and conditions, and hands scientists and coaches new data to dissect — plus the inevitable breathless headlines and humblebragging training plans to follow.
Court restricts abortion access across US by blocking mailing of mifepristone
abcnews - A federal appeals court has restricted access to one of the most common means of abortion in the U.S. by blocking the mailing of mifepristone
AI Summary: A federal appeals court has imposed new limits on distribution of mifepristone, blocking mail-order shipments and narrowing telehealth-based prescribing. The decision immediately complicates access for patients and clinicians who rely on remote care and pharmacy delivery, forcing last‑minute logistical changes, increased travel, and swift legal and policy responses as providers scramble to adapt.
- Appeals court halts mail and telehealth access (4)
- Clinical pivots and drug alternatives amid disruptions (3)
- Supreme Court temporarily restores mail access (5)
- All Other Stories
Appeals court halts mail and telehealth access
Clinical pivots and drug alternatives amid disruptions
Supreme Court temporarily restores mail access
All Other Stories
Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials
Frank Vinluan / medcitynews - Avalayn Pharma found strong investor interest in its inhalable drugs in development for two types of pulmonary fibrosis, enabling the company to upsize its IPO. Data from two mid-stage studies are expected in 2027. The post Avalyn Pharma Takes a Breath to…
AI Summary: Avalyn Pharma has substantially increased its IPO, targeting roughly $300 million to bankroll late-stage trials of its respiratory drug candidate. The move reflects strong investor enthusiasm for lung‑disease therapeutics and gives the company a bigger war chest to advance programs previously dependent on venture capital and partnerships.
AI, face photos may predict cancer survival: Mass General Brigham study
Giles Bruce / beckershospitalreview - Using multiple photos from across a patient’s course of treatment in the FaceAge AI tool may be an even better predictor of survival than a single photo alone, a new Mass General Brigham study found. Researchers behind FaceAge, which uses AI to analyze a …
AI Summary: An AI model trained on clinical cohorts at Mass General Brigham can estimate biological aging from simple facial photos and links accelerated facial aging to poorer cancer survival. The research suggests noninvasive image-based signals could complement standard prognostic markers, offering a surprising, low-cost way to flag higher-risk patients earlier.
Beth Israel Lahey Health taps Heidi for system-wide AI scribe rollout
fiercehealthcare - The scaled deployment follows a six-month trial for 1,000 providers at the Boston-based health system.
AI Summary: Beth Israel Lahey Health is deploying an AI-driven scribe across its network and has appointed a system lead to shepherd the rollout. The initiative aims to reduce clinician documentation burden and streamline workflows, though it also invites debate about accuracy, clinician oversight, and the usual AI-era promises of magical time savings.
- AI leadership, governance and in-house tool strategies (4)
- Ambient AI privacy, nurse concerns and clinical tradeoffs (3)
- Systemwide scribe rollouts and clinical AI deployments (4)
- All Other Stories
AI leadership, governance and in-house tool strategies
Ambient AI privacy, nurse concerns and clinical tradeoffs
Systemwide scribe rollouts and clinical AI deployments
All Other Stories
Matthew Kurian: ODAC Votes 6–3 Against Camizestrant Approval In SERENA-6
oncodaily - Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn: “Breaking: ODAC Votes 6-3 Against Camizestrant Approval […]
AI Summary: An FDA oncology advisory committee delivered a 6–3 vote against approval of camizestrant following review of the SERENA‑6 trial, flagging concerns about the data package and the drug’s claimed “new paradigm.” The panel’s negative recommendation raises serious regulatory and commercial uncertainty for AstraZeneca’s oral SERD program and its path forward.
- Implications for HR+/HER2- treatment landscape (3)
- ODAC rejects camizestrant approval (8)
- All Other Stories
Implications for HR+/HER2- treatment landscape
ODAC rejects camizestrant approval
All Other Stories
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Mergers and Acquisitions, Long COVID, Drug Pricing, Research Funding and look for the RSS link.
StackHealth Time Machine
More StackHealth